Lupin Limited

Lupin Limited (LUPIN) is a mid-cap Healthcare company valued at ₹89,702 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Lupin Limited last traded at ₹1,961.6, modestly down 0.97% on the day.

Recent developments

On 2026-10-08, Lupin received US FDA approval for a vitamin K injection with $52.3 million in annual US sales. On 2026-10-02, Lupin shares hit a 7-week low amid a broad market correction and after Q1 earnings. On 2026-09-24, Lupin released its Q1FY27 earnings call transcript after reporting record results. On 2026-09-22, HSBC noted that Lupin's India business and other markets outside the US are expected to continue showing traction.

Financial performance

Lupin's business is improving, with annual revenue rising 23.1% and net profit surging 62.0% year-over-year. The latest quarter saw revenue grow 32.0% and net profit rise 16.1% compared to the same quarter a year earlier. The net profit margin expanded 4.6 percentage points to 19.2%, while return on equity and return on capital employed remained strong at 23.8% and 25.1%, respectively.

Valuation multiples

The stock trades at 16.8 times earnings, a discount to the Healthcare median of 32.0, 4.23 times book value. It yields 0.9%.

Things to watch

Lupin's stock is 22.7% below its 52-week high. Promoter holding remained at 46.85%, but domestic institutional holding fell 0.67 points in the quarter. The company's recent share price decline and a 7-week low on 2026-10-02 indicate market uncertainty.

Where it stands

Lupin's financials show strong growth, with profit rising 128.7% over three years and 34.2% over five years. The latest quarter's results reflect continued expansion, but the stock is currently 22.7% below its 52-week high. The company's recent regulatory approval and earnings performance highlight its ongoing growth trajectory.

Summarised by DocStoX's model on 2026-10-10 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.